SYH-2053

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameSYH-2053
Drug Alias NameSYH2053SYH-2053
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitorsRNA interference
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaSitosterolemiaHypercholesterolemia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaSitosterolemiaHypercholesterolemia +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A